

Young E Whang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3171839/publications.pdf>

Version: 2024-02-01

65
papers

3,981
citations

156536

32
h-index

134545

62
g-index

68
all docs

68
docs citations

68
times ranked

5778
citing authors

#	ARTICLE	IF	CITATIONS
1	Feasibility of home-based exercise training in men with metastatic castration-resistant prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, , .	2.0	5
2	Body composition, physical function and quality of life in healthy men and across different stages of prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 725-732.	2.0	5
3	Cistrome analysis of YY1 uncovers a regulatory axis of YY1:BRD2/4-PFKP during tumorigenesis of advanced prostate cancer. <i>Nucleic Acids Research</i> , 2021, 49, 4971-4988.	6.5	22
4	A real-world evaluation of radium-223 in combination with abiraterone or enzalutamide for the treatment of metastatic castration-resistant prostate cancer. <i>PLoS ONE</i> , 2021, 16, e0253021.	1.1	6
5	Patterns of Recurrence, Detection Rates, and Impact of 18-F Fluciclovine PET/CT on the Management of Men With Recurrent Prostate Cancer. <i>Urology</i> , 2021, 155, 192-198.	0.5	3
6	Phase II Study of Gemcitabine and Split-Dose Cisplatin Plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 3140-3148.	0.8	72
7	Practical Considerations and Challenges for Germline Genetic Testing in Patients With Prostate Cancer: Recommendations From the Germline Genetics Working Group of the PCCTC. <i>JCO Oncology Practice</i> , 2020, 16, 811-819.	1.4	35
8	Phase I trial of docetaxel plus lutetium-177-labeled anti-“prostate”-specific membrane antigen monoclonal antibody J591 (177Lu-“J591) for metastatic castration-resistant prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 848.e9-848.e16.	0.8	29
9	Pilot Study of [18F] Fluorodeoxyglucose Positron Emission Tomography (FDG-PET)/Magnetic Resonance Imaging (MRI) for Staging of Muscle-invasive Bladder Cancer (MIBC). <i>Clinical Genitourinary Cancer</i> , 2020, 18, 378-386.e1.	0.9	15
10	Cutaneous adverse reactions in B-RAF positive metastatic melanoma following sequential treatment with B-RAF/MEK inhibitors and immune checkpoint blockade or vice versa. A single-institutional case-series. , 2019, 7, 4.		18
11	Dacomitinib, but not lapatinib, suppressed progression in castration-resistant prostate cancer models by preventing HER2 increase. <i>British Journal of Cancer</i> , 2019, 121, 237-248.	2.9	15
12	Germline Genetic Testing in Advanced Prostate Cancer; Practices and Barriers: Survey Results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 275-282.e1.	0.9	42
13	Interaction between androgen receptor and coregulator SLIRP is regulated by Ack1 tyrosine kinase and androgen. <i>Scientific Reports</i> , 2019, 9, 18637.	1.6	7
14	Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. <i>Journal of Clinical Oncology</i> , 2018, 36, 991-999.	0.8	169
15	Phase II trial of palbociclib in patients with metastatic urothelial cancer after failure of first-line chemotherapy. <i>British Journal of Cancer</i> , 2018, 119, 801-807.	2.9	29
16	ZFX Mediates Non-canonical Oncogenic Functions of the Androgen Receptor Splice Variant 7 in Castrate-Resistant Prostate Cancer. <i>Molecular Cell</i> , 2018, 72, 341-354.e6.	4.5	64
17	Cabozantinib-induced serum creatine kinase elevation and musculoskeletal complaints. <i>Investigational New Drugs</i> , 2018, 36, 1143-1146.	1.2	4
18	Discrete microfluidics for the isolation of circulating tumor cell subpopulations targeting fibroblast activation protein alpha and epithelial cell adhesion molecule. <i>Npj Precision Oncology</i> , 2017, 1, .	2.3	29

#	ARTICLE	IF	CITATIONS
19	Androgen Receptor-Dependent and -Independent Mechanisms Involved in Prostate Cancer Therapy Resistance. <i>Cancers</i> , 2017, 9, 67.	1.7	83
20	Application of liquid biopsies to identify genomic factors associated with therapy resistance in castration resistant prostate cancer. <i>Annals of Translational Medicine</i> , 2016, 4, S64-S64.	0.7	1
21	Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistance. <i>Clinical Pharmacology and Therapeutics</i> , 2015, 98, 582-589.	2.3	57
22	Genomic Profiling of Cancers of Unknown Primary Site. <i>JAMA Oncology</i> , 2015, 1, 541.	3.4	4
23	Posterior reversible encephalopathy syndrome induced by enzalutamide in a patient with castration-resistant prostate cancer. <i>Investigational New Drugs</i> , 2015, 33, 751-754.	1.2	18
24	Neoadjuvant chemotherapy administration and time to cystectomy for muscle-invasive bladder cancer: An evaluation of transitions between academic and community settings. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 386.e1-386.e6.	0.8	15
25	Mutation of Androgen Receptor N-Terminal Phosphorylation Site Tyr-267 Leads to Inhibition of Nuclear Translocation and DNA Binding. <i>PLoS ONE</i> , 2015, 10, e0126270.	1.1	12
26	Mechanisms of acquired resistance to androgen receptor targeting drugs in castration-resistant prostate cancer. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 1369-1378.	1.1	30
27	Arrays of high-aspect ratio microchannels for high-throughput isolation of circulating tumor cells (CTCs). <i>Microsystem Technologies</i> , 2014, 20, 1815-1825.	1.2	25
28	Roadmap for the development of the University of North Carolina at Chapel Hill Genitourinary OncoLogY Database—UNC GOLD. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 32.e1-32.e9.	0.8	8
29	A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 82-86.	0.8	74
30	A phase I study of a chimeric monoclonal antibody against interleukin-6, siltuximab, combined with docetaxel in patients with metastatic castration-resistant prostate cancer. <i>Investigational New Drugs</i> , 2013, 31, 669-676.	1.2	54
31	Tolerability, safety and pharmacokinetics of ridaforolimus in combination with bicalutamide in patients with asymptomatic, metastatic castration-resistant prostate cancer (CRPC). <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 72, 909-916.	1.1	20
32	Phase I study of concurrent weekly docetaxel, high-dose intensity-modulated radiation therapy (IMRT) and androgen-deprivation therapy (ADT) for high-risk prostate cancer. <i>BJU International</i> , 2012, 110, E721-6.	1.3	17
33	A multidisciplinary approach to the management of urologic malignancies: Does it influence diagnostic and treatment decisions?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2011, 29, 378-382.	0.8	86
34	Neoadjuvant docetaxel/estramustine prior to radical prostatectomy or external beam radiotherapy in high risk localized prostate cancer: A phase II trial. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2011, 29, 608-613.	0.8	15
35	Response to degarelix after resistance to luteinizing hormone-releasing hormone agonist therapy for metastatic prostate cancer. <i>Anti-Cancer Drugs</i> , 2011, 22, 299-302.	0.7	15
36	A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer. <i>Cancer</i> , 2011, 117, 526-533.	2.0	70

#	ARTICLE	IF	CITATIONS
37	Rapamycin inhibits cell proliferation in type I and type II endometrial carcinomas: A search for biomarkers of sensitivity to treatment. <i>Gynecologic Oncology</i> , 2010, 119, 579-585.	0.6	32
38	A phase II trial of neoadjuvant erlotinib in patients with muscle-invasive bladder cancer undergoing radical cystectomy: clinical and pathological results. <i>BJU International</i> , 2010, 106, 349-354.	1.3	95
39	Neoadjuvant Clinical Trial With Sorafenib for Patients With Stage II or Higher Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2010, 28, 1502-1507.	0.8	185
40	Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 8438-8443.	3.3	223
41	Intercellular Targets of Prostate Cancer. , 2007, , 475-486.		0
42	Involvement of arginine methyltransferase CARM1 in androgen receptor function and prostate cancer cell viability. <i>Prostate</i> , 2006, 66, 1292-1301.	1.2	129
43	The impact of altered annexin I protein levels on apoptosis and signal transduction pathways in prostate cancer cells. <i>Prostate</i> , 2006, 66, 1413-1424.	1.2	57
44	Rapamycin inhibits hTERT telomerase mRNA expression, independent of cell cycle arrest. <i>Gynecologic Oncology</i> , 2006, 100, 487-494.	0.6	29
45	The PTEN tumor suppressor inhibits telomerase activity in endometrial cancer cells by decreasing hTERT mRNA levels. <i>Gynecologic Oncology</i> , 2006, 101, 305-310.	0.6	44
46	Estrogen-receptor-dependent regulation of telomerase activity in human endometrial cancer cell lines. <i>Gynecologic Oncology</i> , 2006, 103, 417-424.	0.6	37
47	Inhibition of HER-2/neu Kinase Impairs Androgen Receptor Recruitment to the Androgen Responsive Enhancer. <i>Cancer Research</i> , 2005, 65, 3404-3409.	0.4	88
48	p38 and EGF receptor kinase-mediated activation of the phosphatidylinositol 3-kinase/Akt pathway is required for Zn ²⁺ -induced cyclooxygenase-2 expression. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2005, 289, L883-L889.	1.3	49
49	Heregulin-Induced Activation of HER2 and HER3 Increases Androgen Receptor Transactivation and CWR-R1 Human Recurrent Prostate Cancer Cell Growth. <i>Clinical Cancer Research</i> , 2005, 11, 1704-1712.	3.2	124
50	Activated Tyrosine Kinase Ack1 Promotes Prostate Tumorigenesis: Role of Ack1 in Polyubiquitination of Tumor Suppressor Wwox. <i>Cancer Research</i> , 2005, 65, 10514-10523.	0.4	186
51	Regulation of Sensitivity to TRAIL by the PTEN Tumor Suppressor. <i>Vitamins and Hormones</i> , 2004, 67, 409-426.	0.7	37
52	Zinc-induced PTEN Protein Degradation through the Proteasome Pathway in Human Airway Epithelial Cells. <i>Journal of Biological Chemistry</i> , 2003, 278, 28258-28263.	1.6	139
53	Renal cell carcinoma. <i>Current Opinion in Oncology</i> , 2003, 15, 213-216.	1.1	24
54	Human epidermal receptor-2 expression in prostate cancer. <i>Clinical Cancer Research</i> , 2003, 9, 1087-97.	3.2	47

#	ARTICLE	IF	CITATIONS
55	Rapamycin inhibits telomerase activity by decreasing the hTERT mRNA level in endometrial cancer cells. <i>Molecular Cancer Therapeutics</i> , 2003, 2, 789-95.	1.9	58
56	PTEN Blocks Tumor Necrosis Factor-induced NF- κ B-dependent Transcription by Inhibiting the Transactivation Potential of the p65 Subunit. <i>Journal of Biological Chemistry</i> , 2002, 277, 11116-11125.	1.6	113
57	Hypertriglyceridemia and Pancreatitis Associated With Estramustine Phosphate. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2002, 25, 342-343.	0.6	7
58	PTEN sensitizes prostate cancer cells to death receptor-mediated and drug-induced apoptosis through a FADD-dependent pathway. <i>Oncogene</i> , 2002, 21, 319-327.	2.6	121
59	Role of Phosphoinositide 3-Kinase in the Aggressive Tumor Growth of HT1080 Human Fibrosarcoma Cells. <i>Molecular and Cellular Biology</i> , 2001, 21, 5846-5856.	1.1	26
60	Functional role for the c-Abl tyrosine kinase in meiosis. <i>Oncogene</i> , 1998, 16, 1773-1777.	2.6	45
61	Identification of a Pseudogene That Can Masquerade as a Mutant Allele of the PTEN/MMAC1 Tumor Suppressor Gene. <i>Journal of the National Cancer Institute</i> , 1998, 90, 859-861.	3.0	28
62	Signal transduction by wild-type and leukemogenic Abl proteins. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 1997, 1333, F201-F216.	3.3	53
63	Role for c-Abl tyrosine kinase in growth arrest response to DNA damage. <i>Nature</i> , 1996, 382, 272-274.	13.7	232
64	Acidities of carboxamides, hydroxamic acids, carbohydrazides, benzenesulfonamides, and benzenesulfonohydrazides in DMSO solution. <i>Journal of Organic Chemistry</i> , 1990, 55, 3330-3336.	1.7	118
65	Epstein-barr virus gp350/220 binding to the B lymphocyte C3d receptor mediates adsorption, capping, and endocytosis. <i>Cell</i> , 1987, 50, 203-213.	13.5	481